Analyst consensus
As at 8 August 2022
FY22
|
|
Low |
High |
Average (Mean) |
|
Revenue (£m) |
1,141.9 |
1,228.0 |
1,176.5 |
|
EBITDA (£m) |
211.2 |
218.0 |
215.0 |
|
EBIT (£m) |
109.7 |
116.9 |
113.5 |
|
PBT (£m) |
20.0 |
29.8 |
24.3 |
|
Net income (£m) |
16.0 |
22.0 |
18.8 |
|
Adjusted EPS (p) |
4.1 |
5.4 |
4.6 |
|
Net bank debt (£m) |
(256.0) |
(179.0) |
(213.8) |
|
Net debt (including lease liabilities) (£m) |
(1,074.5) |
(1,030.0) |
(1,052.0) |
FY23
|
|
Low |
High |
Average (Mean) |
|
Revenue (£m) |
1,184.1 |
1,312.0 |
1,248.0 |
|
EBITDA (£m) |
232.0 |
253.0 |
242.1 |
|
EBIT (£m) |
132.0 |
144.6 |
137.9 |
|
PBT (£m) |
43.9 |
55.3 |
48.5 |
|
Net income (£m) |
33.4 |
39.5 |
36.6 |
|
Adjusted EPS (p) |
8.3 |
9.8 |
9.0 |
|
Net bank debt (£m) |
(231.0) |
(119.0) |
(177.6) |
|
Net debt (including lease liabilities) (£m) |
(1,053.7) |
(983.0) |
(1,016.3) |
The figures shown above are on an adjusted, post IFRS 16 basis. They include estimates from seven analysts at the following institutions who have updated their estimates following Spire Healthcare’s FY21 results: Numis, JP Morgan, Barclays, Berenberg, Jefferies, Peel Hunt and RBC.
